scholarly journals PNEUMONIA : EPIDEMIOLOGI, FAKTOR RISIKO PADA BALITA

2021 ◽  
Author(s):  
WURI RATNA HIDAYANI
Keyword(s):  
Polymerase Chain Reaction ◽  
World Health Organization ◽  
Case Fatality Rate ◽  
Case Fatality ◽  
World Health ◽  
Fatality Rate ◽  
Chain Reaction ◽  
Virus Diseases ◽  
Polymerase Chain ◽  
Health Organization

Kasus pneumonia misterius yang belum diketahui etiologinya dilaporkan pada akhir Desember 2019 di Tiongkok. Terjadi lonjakan kasus dalam waktu relative singkat pasien pneumonia berjumlah 44 pasien dan terus meningkat menjadi ribuan kasus. Kasus ini kemudian diidentifikasikan ke dalam kasus Novel Corona Virus Diseases 19 (COVID 19) (Perhimpunan Dokter Paru Indonesia, 2020). Menurut World Health Organization (WHO) menyatakan bahwa hasil diagnosis tes Polymerase Chain Reaction (PCR) negative dengan tanda klinis infeksi COVID 19 di Kazakhstan dikelompokkan ke dalam perhitungan total COVID 19, pernyataan ini disiarkan sejak tanggal 1 Agustus 2020 dengan laporan adanya kasus pneumonia dengan gejala klinis COVID 19 sebanyak 13.121 kasus dengan kematian sebanyak 152 kematian sehingga Case Fatality Rate (CFR) sebesar 1,16% (Xinshua, 2020). Pada Tahun 2015 di dunia kasus pneumonia mencapai 920.000 jiwa setiap tahunnya dengan arti bahwa ada 2 balita meninggal setiap menitnya. Menurut WHO (2017) menyatakan bahwa terdapat 25.481 kematian karena pernafasan akut atau 17% dari seluruh kematian dunia dan Indonesia merupakan peringkat 7 dunia pada kasus pneumonia (Newswire, 2019).

scholarly journals COVID-19 testing: Essential for tracking infection and helping authority to overcome the challenges of spread

2020 ◽  
Vol 10 (2) ◽  
pp. 90-92
Author(s):  
Rano Mal Piryani ◽  
Suneel Piryani ◽  
Shomeeta Piryani ◽  
Ganesh Dangal ◽  
Muzaherul Huq ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
World Health Organization ◽  
Blood Sample ◽  
Ribonucleic Acid ◽  
World Health ◽  
Chain Reaction ◽  
Infected People ◽  
Highly Sensitive ◽  
Polymerase Chain ◽  
Health Organization

COVID-19 is mainly transmitted through droplet infection and spread very fast compared to SARS-CoV and MERS-CoV. For the countries, it is important to know at what stage the COVID-19 epidem­ic is? So, as to take appropriate steps to contain the epidemic. This will only be known by testing the suspects and contacts of confirmed cases. If there is poor testing, then most of the infected people may remain undetected, however they could spread the virus to hundreds of other people and potential contacts, which could not be known and quarantined in time continuing the spread. If there is quality assured, highly sensitive and specific testing along with adequate isolation and quarantine, then the spread will be limited. There are two types of tests available for COVID-19: the tests directly detecting the viral ribonucleic acid (RNA) collected in nasopharyngeal or throat swabs, and tests detecting antibodies from the blood sample. At this point in time, the polymerase chain reaction (PCR) tests are used for confirmation of the disease while antibodies tests may provide information regarding the prevalence of infection. World Health Organization advices the countries to increase the testing and get to know the level of epidemic and act accordingly for containment of infection.

scholarly journals Trend of case fatality rate during first 30 days of COVID-19 epidemic; the example of Iran

2020 ◽  
Vol 5 (1) ◽  
pp. e05-e05
Author(s):  
Khatereh Anbari ◽  
Seyyed Amir Yasin Ahmadi ◽  
Mitra Elmi
Keyword(s):  
Case Fatality Rate ◽  
Case Fatality ◽  
World Health ◽  
Fatality Rate ◽  
Scientific Databases ◽  
Number Of Patients ◽  
Descriptive Approach ◽  
Polymerase Chain ◽  
Health Organization

Introduction: One of the unusual aspects in coronavirus disease 2019 (COVID-19) pandemic is changing case fatality rate (CFR) in different time series. Many researchers are trying to find the reasons of this variability. Objectives: This study aimed to present a model for a 30-day trend of CFR in any infectious disease epidemic using the example of COVID-19 in Iran. Patients and Methods: As a case study, we tried to use statistical mining of scientific databases. A descriptive approach with quantitative tools was conducted. The World Health Organization (WHO) database was used to access daily reports of CFR. Funnel plot and Z score were used to study and graph the trend. Results: During this period of time, a total of 20610 cases were confirmed based on real-time polymerase chain reaction (PCR). Among them, 1556 individuals died. Therefore, CFR was calculated as 7.549% (95% confidence intervals 7.189%-7.910%). This frequency was considered as the pooled frequency. Daily CFR with 95% CI was compared with the pooled frequency. Conclusion: In our case, the epidemic was started from high CFR due to low number of cases and testing only highly suspicious individuals. Then, the CFR was reduced due to increased number of patients and improvement in screening. Finally, CFR went back to its moderate rate due to the addition of the death numbers related to the cases of previous days.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood ◽  
2010 ◽  
Vol 116 (22) ◽  
pp. e111-e117 ◽  
Author(s):  
Helen E. White ◽  
Paul Matejtschuk ◽  
Peter Rigsby ◽  
Jean Gabert ◽  
Feng Lin ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
World Health Organization ◽  
Real Time ◽  
Quantitative Polymerase Chain Reaction ◽  
Reference Panel ◽  
World Health ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Health Organization ◽  
First World

Serial quantitation of BCR-ABL mRNA levels is an important indicator of therapeutic response for patients with chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia, but there is substantial variation in the real-time quantitative polymerase chain reaction methodologies used by different testing laboratories. To help improve the comparability of results between centers we sought to develop accredited reference reagents that are directly linked to the BCR-ABL international scale. After assessment of candidate cell lines, a reference material panel comprising 4 different dilution levels of freeze-dried preparations of K562 cells diluted in HL60 cells was prepared. After performance evaluation, the materials were assigned fixed percent BCR-ABL/control gene values according to the International Scale. A recommendation that the 4 materials be established as the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL translocation by real-time quantitative polymerase chain reaction was approved by the Expert Committee on Biological Standardization of the World Health Organization in November 2009. We consider that the development of these reagents is a significant milestone in the standardization of this clinically important test, but because they are a limited resource we suggest that their availability is restricted to manufacturers of secondary reference materials.

scholarly journals VAKSINASI MASAL COVID-19 DI UNIVERSITAS MUHAMMADIYAH MATARAM KOTA MATARAM PROVINSI NUSA TENGGARA BARAT

2021 ◽  
Vol 5 (1) ◽  
pp. 713
Author(s):  
Evi Diliana Rospia ◽  
Dwi Kartika Cahyaningtyas ◽  
Desi Rofita ◽  
Cahaya Indah Lestari ◽  
Ni Wayan Ari Adi Putri ◽  
...  
Keyword(s):  
World Health Organization ◽  
Case Fatality Rate ◽  
Herd Immunity ◽  
Case Fatality ◽  
Mass Vaccination ◽  
World Health ◽  
Fatality Rate ◽  
First Case ◽  
Difficulty Breathing ◽  
Health Organization

ABSTRAKNovel coronavirus 2019 atau virus corona sindrom pernafasan akut parah yang disebut COVID-19. Gejala klinis utama yang muncul yaitu demam, batuk dan kesulitan bernapas. World Health Organization (WHO) melaporkan 11.84.226 kasus konfirmasi dengan 545.481 kematian di seluruh dunia (Case Fatality Rate/CFR 4,6%). Di Indonesia kasus meningkat dan menyebar dengan cepat, kasus pertama pada tanggal 2 Maret 2020, pada tanggal 9 Juli 2020 Kementerian Kesehatan melaporkan 70.736 kasus konfirmasi COVID-19 dengan 3.417 kasus meninggal (CFR 4,8%). Kegiatan vaksinasi masal ini bertujuan terbentuknya herd immunity (kekebalan kelompok) dan berkurangnya angka kematian akibat COVID-19 pada masyarakat. Kegiatan vaksinasi masal dilaksanakan di Universitas Muhammadiyah Mataram Kota Mataram Nusa Tenggara Barat, dan jenis vaksin yang digunakan pada kegiatan vaksinasi masal ini adalah Sinovac. Jumlah responden yang mengikuti kegiatan ini sebanyak 1.000 orang. Hasil pengabdian didapatkan jumlah yang melakukan vaksinasi sebanyak 1000 orang yang terdiri dari masyarakat umum dan karyawan Universitas Muhammadiyah Mataram. Kata kunci: vaksinasi; covid-19; komunitas; indonesia. ABSTRACTNovel coronavirus 2019 or severe acute respiratory syndrome coronavirus called COVID-19. The main symptoms that appear are fever, cough and difficulty breathing. The World Health Organization (WHO) reports 11,84,226 confirmed cases with 545,481 deaths worldwide (Case Fatality Rate/CFR 4.6%) In Indonesia cases are increasing and spreading rapidly, the first case on March 2, 2020, on July 9 2020 The Ministry of Health reported 70,736 confirmed cases of COVID-19 with 3,417 deaths (CFR 4.8%). This mass vaccination activity aims to form herd immunity and reduce the death rate due to COVID-19 in the community. The mass vaccination activity was carried out at the Muhammadiyah University of Mataram, and the type of vaccine used in this mass vaccination activity was Sinovac. The number of respondents who participated in this activity was 1,000 people. The results of the service found that the number of people who vaccinated was 1000 people consisting of the general public and employees of the Muhammadiyah University of Mataram. Keywords: vaccination; covid-19; community; indonesia. 

scholarly journals A Case of Covid-19 Patient Presenting with Gastrointestinal-Specific Symptoms in Indonesia

2020 ◽  
Vol 21 (2) ◽  
pp. 153-157
Author(s):  
Daniel Martin Simadibrata ◽  
Cleopas Martin Rumende ◽  
Rahmad Mulyadi ◽  
Marcellus Simadibrata
Keyword(s):  
Infectious Disease ◽  
World Health Organization ◽  
Case Fatality Rate ◽  
Case Fatality ◽  
World Health ◽  
Fatality Rate ◽  
The World ◽  
Health Organization ◽  
Atypical Presentations ◽  
Specific Symptoms

Coronavirus disease 2019 (COVID-19) is an emerging infectious disease officially declared as a pandemic on 11 March 2020 by the World Health Organization (WHO). Indonesia’s COVID-19 case fatality rate remain consistently high, approximately twice the global case fatality rate available. Patients typically present with fever, dry cough and dyspnea. However, there were reports of atypical COVID-19 symptoms such as myalgia, fatigue, diarrhea, nausea, and vomiting. These atypical presentations were suggested to indicate a more severe COVID-19. Here, we present a case of COVID-19 patient presenting with gastrointestinal-specific symptoms in Indonesia.

scholarly journals Epidemiology of Diphtheria in Yemen, 2017-2018: Surveillance Data Analysis (Preprint)

2021 ◽  
Author(s):  
Suaad Ameen Moghalles ◽  
Basher Ahmed Aboasba ◽  
Mohammed Abdullah Alamad ◽  
Yousef Saleh Khader
Keyword(s):  
World Health Organization ◽  
Vaccination Coverage ◽  
Case Fatality Rate ◽  
Case Fatality ◽  
World Health ◽  
Age Group ◽  
Fatality Rate ◽  
Probable Case ◽  
The World ◽  
Health Organization

BACKGROUND As a consequence of war and the collapse of the health system in Yemen, which prevented many people from accessing health facilities to obtain primary health care, vaccination coverage was affected, leading to a deadly diphtheria epidemic at the end of 2017. OBJECTIVE This study aimed to describe the epidemiology of diphtheria in Yemen and determine its incidence and case fatality rate. METHODS Data were obtained from the diphtheria surveillance program 2017-2018, using case definitions of the World Health Organization. A probable case was defined as a case involving a person having laryngitis, pharyngitis, or tonsillitis and an adherent membrane of the tonsils, pharynx, and/or nose. A confirmed case was defined as a probable case that was laboratory confirmed or linked epidemiologically to a laboratory-confirmed case. Data from the Central Statistical Organization was used to calculate the incidence per 100,000 population. A <i>P</i> value &lt;.05 was considered significant. RESULTS A total of 2243 cases were reported during the period between July 2017 and August 2018. About 49% (1090/2243, 48.6%) of the cases were males. About 44% (978/2243, 43.6%) of the cases involved children aged 5 to 15 years. Respiratory tract infection was the predominant symptom (2044/2243, 91.1%), followed by pseudomembrane (1822/2243, 81.2%). Based on the vaccination status, the percentages of partially vaccinated, vaccinated, unvaccinated, and unknown status patients were 6.6% (148/2243), 30.8% (690/2243), 48.6% (10902243), and 14.0% (315/2243), respectively. The overall incidence of diphtheria was 8 per 100,000 population. The highest incidence was among the age group &lt;15 years (11 per 100,000 population), and the lowest incidence was among the age group ≥15 years (5 per 100,000 population). The overall case fatality rate among all age groups was 5%, and it was higher (10%) in the age group &lt;5 years. Five governorates that were difficult to access (Raymah, Abyan, Sa'ada, Lahj, and Al Jawf) had a very high case fatality rate (22%). CONCLUSIONS Diphtheria affected a large number of people in Yemen in 2017-2018. The majority of patients were partially or not vaccinated. Children aged ≤15 years were more affected, with higher fatality among children aged &lt;5 years. Five governorates that were difficult to access had a case fatality rate twice that of the World Health Organization estimate (5%-10%). To control the diphtheria epidemic in Yemen, it is recommended to increase routine vaccination coverage and booster immunizations, increase public health awareness toward diphtheria, and strengthen the surveillance system for early detection and immediate response.

scholarly journals Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection

2021 ◽  
Vol 33 (8) ◽  
pp. 1718-1722
Author(s):  
Alberto Boretti
Keyword(s):  
Case Fatality Rate ◽  
Case Fatality ◽  
Severe Pneumonia ◽  
World Health ◽  
Fatality Rate ◽  
Late Infection ◽  
Western Countries ◽  
Asymptomatic Patients ◽  
Overwhelming Evidence ◽  
Health Organization

This work summarizes the available evidence of the use of chloroquine/hydroxychloroquine (CQ/HCQ) in SARS-CoV-2 infection. Most of the published works indicate CQ/HCQ is likely effective against SARS-CoV-2 infection, almost 100% in prophylaxis and mild-medium severity cases and 60% in late infection cases. The percentage of positive works is larger if those works conducted under a probable conflict of interest are excluded from the list. Despite this overwhelming evidence from independent studies, the use of CQ/HCQ is currently limited or prevented in many western countries, based on a very singular examination of the science. The case of a work published in late May 2020, despite being openly defective and then retracted, prompted the World Health Organization (WHO) to ban the use of CQ/HCQ. This position has not yet rectified, thanks to the results of the not less questionable RECOVERY trial, where very sick patients were administered more than double the dose, over more than double the time, recommended for asymptomatic patients in current protocols of other countries, where CQ/HCQ are used for asymptomatic and mild but not severe pneumonia critically ill patients. While the case fatality rate does not depend only on therapies, it is finally shown based on the number of cases and fatalities per million and the case fatality rate as the western countries enforcing the ban on CQ/HCQ did not perform better, but much worse, than other countries, also because of therapies.

scholarly journals The influence of SARS-CoV-2 variants of concern on national case fatality rates

2021 ◽  
Author(s):  
William A. Barletta
Keyword(s):  
Case Fatality Rate ◽  
Temporal Dynamics ◽  
Case Fatality ◽  
Quantitative Measure ◽  
The United States ◽  
World Health ◽  
Fatality Rate ◽  
Wide Spread ◽  
The Face ◽  
Health Organization

AbstractBackgroundDuring 2021 several new variants of the SARS-CoV-2 virus appeared with both increased levels of transmissibility and virulence with respect to the original wild variant. The Delta (B.1.617.2) variation, first seen in India, dominates COVID-19 infections in several large countries including the United States and India. Most recently, the Lambda variant of interest with increased resistance to vaccines has spread through much of South America.ObjectiveThis research explores the degree to which new variants of concern 1) generate spikes and waves of fluctuations in the daily case fatality rates (CFR) across countries in several regions in the face of increasing levels of vaccination of national populations and 2) may increase the vulnerability of persons with certain comorbidities.MethodsThis study uses new, openly available, epidemiological statistics reported to the relevant national and international authorities for countries across the Americas, Europe, Africa, Asia and the Middle East. Daily CFRs and correlations of fatal COVID-19 infections with potential cofactors are computed for the first half of 2021 that has been dominated by the wide spread of several “variants of concern” as denoted by the World Health Organization.ResultsThe analysis yields a new quantitative measure of the temporal dynamics of mortality due to SARS-CoV-2 infections in the form of variations of a proxy case fatality rate compared on a country to-country basis in the same region. It also finds minimal variation of correlation between the cofactors based on WHO data and on the average apparent case fatality rate.

scholarly journals Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis

2019 ◽  
Vol 18 ◽  
pp. 153303381982839 ◽  
Author(s):  
Moritz Perrech ◽  
Lena Dreher ◽  
Gabriele Röhn ◽  
Pantelis Stavrinou ◽  
Boris Krischek ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Western Blot ◽  
Real Time ◽  
Blot Analysis ◽  
Western Blot Analysis ◽  
Idh1 Mutation ◽  
World Health ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Health Organization

To date, diagnosis of IDH1 mutation is based on DNA sequencing and immunohistochemistry, methods limited in terms of sensitivity and ease of use. Recently, the diagnosis of IDH1 mutation by real-time polymerase chain reaction was introduced as an alternative method. In this study, real-time polymerase chain reaction was validated as a tool for detection of IDH1 mutation, and expression levels were analyzed for correlation with course of the disease. A total of 113 tumor samples were obtained intraoperatively from 84 patients with glioma having a diagnosis of diffuse glioma (World Health Organization II), anaplastic glioma (World Health Organization III), secondary glioblastoma ± chemotherapy, primary glioblastoma ± chemotherapy (World Health Organization IV). Tumor samples were snap frozen and processed for sectioning and RNA and protein isolation. Presence of IDH1 mutation was determined by DNA sequencing. Hereafter, quantitative expression of IDH1 messenger RNA was assessed using real-time polymerase chain reaction with specific primers for IDH1 mutation and –wt; protein expression was verified by Western Blot analysis and immunohistochemistry. Additionally, 19 samples of low-grade glioma and their consecutive high-grade glioma were analyzed at different time points of the disease. IDH1 mutation was identified in 63% of samples by DNA sequencing. In correlation with the real-time polymerase chain reaction results, a cutoff value was determined. Above this threshold, sensitivity and specificity of real-time polymerase chain reaction in detecting IDH1 mutation were 98% and 94%, respectively. Quantitative analysis revealed that IDH1 mutation expression is upregulated in secondary glioblastoma (mean ± standard error of mean: 3.52 ± 0.55) compared to lower grade glioma (II = 1.54 ± 0.22; III = 1.67 ± 0.23). In contrast, IDH1 wt expression is upregulated in all glioma grades (concentration >0.1) compared to control brain tissue (0.007 ± 0.0016). Western Blot analysis showed a high concordance to both sequencing and real-time polymerase chain reaction results in qualitative analysis of IDH1 mutation status (specificity 100% and sensitivity 100%). Moreover, semiquantitative protein expression analysis also showed higher expression levels of mutated IDH1 in secondary glioblastoma. In our study, real-time polymerase chain reaction and Western Blot analysis were found to be highly efficient methods in detecting IDH1 mutation in glioma samples. As cost-effective and time-saving methods, real-time polymerase chain reaction and Western Blot analysis may therefore play an important role in IDH1 mutation analysis in the future. IDH1 mutation expression level was found to correlate with the course of disease to a certain extent. Yet, clinical factors as recurrent disease or prior radiochemotherapy did not alter IDH1 mutation expression level.

Sign in / Sign up

Export Citation Format

Share Document